Johnson & Johnson (JNJ): Price and Financial Metrics


Johnson & Johnson (JNJ): $168.23

-0.66 (-0.39%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

JNJ POWR Grades

  • Quality is the dimension where JNJ ranks best; there it ranks ahead of 94.42% of US stocks.
  • JNJ's strongest trending metric is Growth; it's been moving down over the last 177 days.
  • JNJ's current lowest rank is in the Momentum metric (where it is better than 22.96% of US stocks).

JNJ Stock Summary

  • JOHNSON & JOHNSON's market capitalization of $441,560,136,386 is ahead of 99.76% of US-listed equities.
  • JNJ's went public 37.1 years ago, making it older than 93.53% of listed US stocks we're tracking.
  • In terms of volatility of its share price, JNJ is more volatile than just 0.75% of stocks we're observing.
  • Stocks that are quantitatively similar to JNJ, based on their financial statements, market capitalization, and price volatility, are XOM, UNH, TSM, LLY, and JPM.
  • JNJ's SEC filings can be seen here. And to visit JOHNSON & JOHNSON's official web site, go to www.jnj.com.

JNJ Valuation Summary

  • In comparison to the median Healthcare stock, JNJ's EV/EBIT ratio is 107.07% higher, now standing at 20.5.
  • JNJ's price/earnings ratio has moved down 4.8 over the prior 243 months.

Below are key valuation metrics over time for JNJ.

Stock Date P/S P/B P/E EV/EBIT
JNJ 2023-01-20 4.6 5.9 23.0 20.5
JNJ 2023-01-19 4.6 5.9 23.1 20.6
JNJ 2023-01-18 4.6 5.9 23.2 20.6
JNJ 2023-01-17 4.7 6.0 23.5 20.9
JNJ 2023-01-13 4.7 6.1 23.7 21.1
JNJ 2023-01-12 4.7 6.1 23.7 21.1

JNJ Growth Metrics

    Its 3 year revenue growth rate is now at 16.28%.
  • The year over year cash and equivalents growth rate now stands at -17.43%.
  • Its 4 year net income to common stockholders growth rate is now at 2.98%.
Over the past 67 months, JNJ's revenue has gone up $23,867,000,000.

The table below shows JNJ's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 96,041 21,576 19,157
2022-06-30 95,588 23,582 18,366
2022-03-31 94,880 23,315 19,830
2021-12-31 93,775 23,410 20,878
2021-09-30 91,446 26,021 17,880
2021-06-30 89,190 26,114 17,767

JNJ's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • JNJ has a Quality Grade of B, ranking ahead of 92.45% of graded US stocks.
  • JNJ's asset turnover comes in at 0.52 -- ranking 78th of 682 Pharmaceutical Products stocks.
  • CBIO, CLSD, and ABBV are the stocks whose asset turnover ratios are most correlated with JNJ.

The table below shows JNJ's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-10-03 0.520 0.675 0.295
2021-07-04 0.514 0.670 0.302
2021-04-04 0.498 0.662 0.273
2021-01-03 0.501 0.656 0.272
2020-09-27 0.504 0.657 0.332
2020-06-28 0.514 0.657 0.307

JNJ Price Target

For more insight on analysts targets of JNJ, see our JNJ price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $187.95 Average Broker Recommendation 1.53 (Moderate Buy)

JNJ Stock Price Chart Interactive Chart >

Price chart for JNJ

JNJ Price/Volume Stats

Current price $168.23 52-week high $186.69
Prev. close $168.89 52-week low $155.72
Day low $167.77 Volume 6,058,100
Day high $168.87 Avg. volume 6,980,572
50-day MA $175.47 Dividend yield 2.69%
200-day MA $173.05 Market Cap 439.83B

Johnson & Johnson (JNJ) Company Bio


Founded in 1886, Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture, and sale of products in the healthcare field within its Consumer, Pharmaceutical and Medical Devices segments. The Consumer segment consists of skin and self-care product brand names such as Aveeno, Neutrogena, Rogaine, Tylenol, Motrin, Listerine, and Band-Aid. Johnson’s Pharmaceutical segment contains biopharma products that address immune, cardiovascular, metabolic, and infectious disease medical conditions. The Medical Device segment develops products centered around orthopedic, surgical, intervention, and vision solutions. The company has over 130,000 employees worldwide and is headquartered in New Brunswick, New Jersey. The company’s current Chief Executive Officer is Alex Gorsky.


JNJ Latest News Stream


Event/Time News Detail
Loading, please wait...

JNJ Latest Social Stream


Loading social stream, please wait...

View Full JNJ Social Stream

Latest JNJ News From Around the Web

Below are the latest news stories about JOHNSON & JOHNSON that investors may wish to consider to help them evaluate JNJ as an investment opportunity.

Johnson & Johnson (JNJ) is a Top Dividend Stock Right Now: Should You Buy?

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.

Yahoo | January 25, 2023

Stock Market News for Jan 25, 2023

Wall Street closed mixed on Tuesday as investors digested the latest batch of corporate earnings reports and gauged the state of the economy.

Yahoo | January 25, 2023

3 Reasons Why Johnson & Johnson Stock Could Rebound After a Bad Start in 2023

It's the opposite story, though, for Johnson & Johnson (NYSE: JNJ): Shares of the healthcare giant rose 3% in 2022 but have declined so far this year. The impact of COVID-19 continued to weigh on Johnson & Johnson in its latest quarter. No, Johnson & Johnson isn't likely to experience a significant sales bounce with its COVID vaccine.

Yahoo | January 25, 2023

FTSE closes in the red as Wall Street lower amid earnings concern

London’s blue-chip index fnished in the red.

Yahoo | January 25, 2023

Most Active Equity Options For Midday - Tuesday, Jan. 24

Here are the most active equity options for midday.

TalkMarkets.com | January 24, 2023

Read More 'JNJ' Stories Here

JNJ Price Returns

1-mo -5.25%
3-mo -3.18%
6-mo -1.99%
1-year 0.50%
3-year 20.77%
5-year 33.64%
YTD -4.77%
2022 5.97%
2021 11.44%
2020 10.82%
2019 16.22%
2018 -5.13%

JNJ Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full JNJ Dividend History

Continue Researching JNJ

Want to see what other sources are saying about Johnson & Johnson's financials and stock price? Try the links below:

Johnson & Johnson (JNJ) Stock Price | Nasdaq
Johnson & Johnson (JNJ) Stock Quote, History and News - Yahoo Finance
Johnson & Johnson (JNJ) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5917 seconds.